Parsons Capital Management Inc Ligand Pharmaceuticals Inc Transaction History

Parsons Capital Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 10, 2020	SELL	$68.28 - $123.65 $239,321 - $433,393	-3,505 Closed	0 $0
Q1 2020 May 05, 2020	SELL	$63.37 - $107.88 $21,862 - $37,218	-345 Reduced 8.96%	3,505 $255,000
Q3 2019 Nov 12, 2019	SELL	$86.25 - $120.16 $8,625 - $12,016	-100 Reduced 2.53%	3,850 $383,000
Q2 2019 Aug 01, 2019	SELL	$107.38 - $129.34 $4,832 - $5,820	-45 Reduced 1.13%	3,950 $451,000
Q1 2019 Apr 26, 2019	BUY	$105.93 - $142.47 $3,177 - $4,274	30 Added 0.76%	3,995 $502,000
Q4 2018 Feb 01, 2019	BUY	$128.36 - $272.13 $45,567 - $96,606	355 Added 9.83%	3,965 $538,000
Q2 2018 Aug 09, 2018	SELL	$150.77 - $207.98 $8,593 - $11,854	-57 Reduced 1.55%	3,610 $0
Q3 2017 Oct 26, 2017	BUY	$120.91 - $137.94 $443,376 - $505,825	3,667	3,667 $499,000

256

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.83B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Parsons Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Parsons Capital Management Inc with notifications on news.